Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer

Clinical Interventions in Aging

Volumn 3, Issue 4, 2008, Pages 647-657

  Gonnelli, Stefano ^a   Petrioli, Roberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Aromatase inhibitors; Bone loss; Breast cancer; Cardiovascular risk; Lipids

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CALCIUM; EXEMESTANE; FULVESTRANT; LETROZOLE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FRACTURE; FRAGILITY FRACTURE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

AROMATASE INHIBITORS; BONE AND BONES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LIPID METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RISK FACTORS;

EID: 60749114852     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group 2005. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-2.
2. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group 2008. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 9:45-53.
3. Atalay G, Dirix L, Biganzoli L, et al. 2004. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. Ann Oncol, 15:211-7.
4. Bajetta E, Zilembo N, Bichisao E. 2002. Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. J Clin Oncol, 20:3039-40.
5. Baum M, Buzdar AU, Cuzick J, et al. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359:2131-9.
6. Boccardo F, Rubagotti A, Guglielmini P, et al. 2006. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol, 17:10-4.
7. Bonneterre J, Buzdar A, Nabholtz JM, et al. 2001. Anastrozole is superior to tamoxifen as first-line therapy in hormone-receptor positive advanced breast carcinoma. Cancer, 92:2247-58.
8. Braithwaite RS, Chlebowski RT, Lau J, et al. 2003. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med, 18:937-74.
9. Bria E, Ciccarese M, Giannarelli D, et al. 2006. Early switch with aromatase inhibitors as adjuvant hormonal theraphy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev, 32:325-32.
10. Brufsky A, Marker WG, Beck JT, et al. 2007. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol, 25:828-36.
11. Brufsky A.M. 2008. Cancer treatment induced bone loss: pathophysiology and clinical perspectives. The Oncologist, 13:187-95.
12. Burstein HJ. 2007. Aromatase inhibitor-associated arthralgia syndrome. Breast, 16:223-34.
13. Buzdar A, Howell A. 2001. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res, 7:2620-35.
14. Carlini P, Bria E, Ferretti G, et al. 2005. New aromatase inhibitors (Ais) as first-line endocrine therapy (ET) in metastatic breast cancer (MBC): A pooled analysis of 3238 women from 8 phase III trials. ASCO 2005, 23:602.
15. Cataliotti L, Buzdar AU, Noguchi S, et al. 2006. Comparison of anastrozole versus tamoxifen as pre-operative therapy in postmenopausal women with hormone teceptor-positiev breast cancer: the pre-operative 'Arimidex' compared to tamoxifen (PROACT) trial. Cancer, 106:2095-103.
16. Clarke M. 2006. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol, 17:59-62.
17. Coates AS, Keshaviah A, Thulimann B, et al. 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol, 25:486-92.
18. Coleman RE, Banks LM, Girgis SI, et al. 2007. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol, 8:119-27.
19. Coleman RE, Bolten WW, Lansdown M, et al. 2008. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev, 34:275-82.
20. Confavreux C, Fontana A, Guastalla JP, et al. 2007. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone, 41:346-52.
21. Coombes RC, Kilburn LS, Snowdon CF, et al. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369:559-70.
22. Cummings SR, Browner WS, Bauer D, et al. 1998. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med, 339:733-8.
23. Cuzick J, Powles T, Veronesi U, et al. 2003. Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361:296-300.
24. Eastell R, Hannon RA, Cuzick J, et al. 2006. Effects on an Aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res, 21:1215-23.
25. Elisaf MS, Bairaktari ET, Nicolaides C, et al. 2001. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer, 37:1510-3.
26. Engan T, Krane J, Johannessen DC, et al. 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat, 36:287-97.
27. Francini G, Petrioli R, Montagnani A, et al. 2006. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effect on body composition and lipid. Br J Cancer, 95:153-8.
28. Ganz PA. 2001. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst, 30:130-4.
29. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. 2007. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone responsive breast cancer: a report from Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25:820-8.
30. Gonnelli S, Cadirni A, Caffarelli C, et al. 2007. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone, 40:205-10.
31. Goss PE, Ingle JN, Martino S, et al. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N Eng J Med, 349:1793-802.
32. Goss PE, Ingle JN, Martino S, et al. 2005. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer; updated findings from NCIC CTG MA. 17. J Natl Cancer Inst, 97:1262-71.
33. Goss PE, Hadji P, Subar M, et al. 2007. Effects of steroidal and nonsteroidal aromatase inhitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res, 9:R52.
34. Heshmati HM, Khosla S, Robins SP, et al. 2002. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res, 17:172-8.
35. Hillner BE, Ingle JN, Chlebowski RT, et al. 2003. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 21:4042-4057.
36. Jakesz R, Jonat W, Gnant M, et al. 2005. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366:455-62.
37. Jakesz R, Greil R, Gnant M, et al. 2007. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst, 19:1845-53.
38. Jordan VC 2007. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids, 72:829-42.
39. Journé F, Body JJ, Leclercq G, et al. 2008. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health. Expert Opin Drug Saf, 7:241-58.
40. Kaufmann M, Jonat W, Hilfrich J, et al. 2007. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol, 25:2664-70.
41. Liu CL, Yang TL. 2003. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat, 79:11-6.
42. Lonning PE, Geisler J, Krag LE, et al. 2005. Effects of exemestane administred for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol, 23:5126-37.
43. Love RR, Wiebe DA, Feyzi JM, et al. 1994. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst, 86:1534-9.
44. Mavrokokki T, Cheng A, Stein B, et al. 2007. Nature and frequency of bisphosphonates-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg, 65:415-23.
45. Manson JE, Hsia J, Johnson KC, et al. 2003. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med, 349:523-34.
46. Markopoulos C, Polychronis A, Zobolas V, et al. 2005. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat, 93:61-6.
47. McCloskey E. 2006. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer, 42:1044-51.
48. Mincey BA, Duh MS, Thomas SK, et al. 2006. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer, 7:127-32.
49. Montagnani A, Gonnelli S, Cadirni A, et al. 2007. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. in press 10.1016/j.ejim.2007.05.016
50. Mouridsen H, Gershanovich M, Sun Y, et al. 2001. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 14:2000-11.
51. Mouridsen H, Keshaviah A, Coates AS, et al. 2007. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Onco, 25:5715-22.
52. Nabholtz JM, Buzdar A, Pollak M, et al. 2000. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial-Arimidex Study Group. J Clin Oncol, 18:3758-67.
53. Neven P, Paridaens R, Pelgrims G, et al. 2008. Fulvestrant (Faslodextrade mark) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat, 109:59-65.
54. Pavlakis N, Schmidt RL, Stockler M. 2005. Bisphosphonates for breast cancer. Cochrance Database Syst Rev, (3):CD003474.
55. Perez EA, Josse RG, Pritchard KI, et al. 2006. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol, 24:3629-35.
56. Ponzone R, Mininanni P, Cassina E, et al. 2008. Aromatase inhibitors for breast cancer: different structures, same effects? Endocrine-Related Cancer, 15:27-36.
57. Rosano GM, Chierchia SL, Leonardo F, et al. 1996. Cardioprotective effects of ovarian hormones. Eur Heart J, 17:15-9.
58. Sawada S, Sato K. 2003. Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat, 82:S31-2.
59. Smith IE, Dowsett M. 2003. Aromatase inhibitors in breast cancer. N Engl J Med, 348:2431-42.
60. Thurlimann B, Keshaviah A, Coates AS, et al. 2005. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 353:2747-57.
61. Viale G, Regan MM, Maiorano E, et al. 2007. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: results from the BIG 1-98 collaborative groups. J Clin Oncol, 25:3846-52.
62. Weitzman R, Sauter N, Eriksen EF, et al. 2007. Critical review: Updated recommendations fort he prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol, 62:148-52.
63. Winer EP, Hudis C, Burstein HJ, et al. 2004. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol, 23:619-9.